Clinical Trial Update: Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating selinexor with docetaxel in non-small cell lung cancer was terminated, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Selinexor (selinexor)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-13